Pfizer Restructures for a More Flexible Future

In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care, and emerging markets. These units join Pfizer's oncology and mature products businesses.

In a move that could position Pfizer Inc. for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care, and emerging markets.

The Pfizer restructuring news—leaked by design more than announced—followed by a week the revelation that the Big Pharma was exiting...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo